Market Introduction
Point-of-care molecular diagnostics include portable devices, and assays & kits used to detect and diagnose diseases in human samples, such as throat swab, blood, serum, and stool. Molecular diagnostics are shifting from centralized laboratories to decentralized point-of-care molecular testing. Due to its simplicity, convenience, rapid turnaround time, and potential to improve patient outcomes, POCT is rapidly gaining traction.
Moreover, the growing demand for specific viral detection methods that consume less time for timely infection control is expected to bolster the market growth during the forecast period.
South Africa has reported the highest COVID-19 cases in the Middle East and Africa, followed by Saudi Arabia and the UAE, among others. The Saudi government policies have been favoring the proliferation of domestic pharmaceutical manufacturers; the government has lifted import duties on raw materials and intermediate products and made financing easy by supporting interest-free funding. Similarly, the continuously increasing incidence of COVID-19 is creating a huge demand for kits and reagent used in its diagnosis. In April 2020, BGI Group, a Chinese genomics company, and Group-42, a UAE technology company, unveiled a new massive-throughput laboratory in the UAE to support testing and diagnosis of the novel coronavirus. According to the BGI Group, the lab will use RT-PCR diagnostic kits that have been approved by medical regulatory authorities in China, Europe, the US, and Japan. As point-of-care molecular diagnostics kits are majorly used in the detection of SARS-CoV-2, the pandemic is fueling the market growth.
Market Overview and Dynamics
The Middle East & Africa Point-of-Care Molecular Diagnostics market is expected to reach US$ 212.9 million by 2028 from US$ 94.0 million in 2021. The market is estimated to grow at a CAGR of 12.4% from 2021–2028. Point-of-care (POC) molecular tests are accurate and scalable that increase the scope for the diagnosis of diseases, which can be done in the community and outside the laboratory setting. Compared with laboratory testing, point-of-care molecular diagnostics provides various advantages such as fewer clinic visits, shorter hospital stays, better drug therapy optimization, and less inappropriate drug use. The healthcare sector is undergoing huge transformation due to the emergence of new and effective technologies across the sector. Thus, the growing demand for effective diagnostics that consumes less time than laboratory testing drives the demand for POC molecular assays and kits propelling the growth of Middle East & Africa point-of-care molecular diagnostics market over the forecast period.
Key Market Segments
In terms of product & services, the assays and kits segment accounted for the largest share of the Middle East & Africa Point-of-Care Molecular Diagnostics market in 2020. In terms of technology, the PCR segment accounted for the largest share of the Middle East & Africa Point-of-Care Molecular Diagnostics market in 2020. In terms of application, the infectious diseases segment accounted for the largest share of the Middle East & Africa Point-of-Care Molecular Diagnostics market in 2020. In terms of end user, the diagnostic laboratories segment accounted for the largest share of the Middle East & Africa Point-of-Care Molecular Diagnostics market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Point-of-Care Molecular Diagnostics market in Middle East & Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are bioMérieux SA, F. Hoffmann-La Roche Ltd., Danaher Corporation, Enzo Biochem, Inc., Abbott, Meridian BioScience, Inc., Biocartis, Quidel Corporation, and Bio-Rad Laboratories, Inc.
Reasons to Buy Report
- To understand the Middle East & Africa Point-of-Care Molecular Diagnostics market landscape and identify market segments that are likely to guarantee a strong return
- To comprehend the ever-changing market landscape and stay ahead in competition
- To efficiently plan merger and acquisition, and partnership deals in the Middle East & Africa Point-of-Care Molecular Diagnostics market by identifying segments with the most promising probable sales
- To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
- To obtain market revenue forecast of the Middle East & Africa Point-of-Care Molecular Diagnostics market based on various segments for the period 2021–2028
MIDDLE EAST & AFRICA POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
By Technology
- PCR
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Other Technologies
By Application
- Infectious Diseases
- Oncology
- Hematology
- Prenatal Testing
- Endocrinology
- Other Applications
By End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Research and Academic Institutes
- Others
By Country
- Middle East & Africa
-
-
-
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
-
-
Companies Mentioned
- bioMérieux SA
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Enzo Biochem, Inc.
- Abbott
- Meridian BioScience, Inc.
- Biocartis
- Quidel Corporation
- Bio-Rad Laboratories, Inc.
Middle East and Africa Point-of-Care Molecular Diagnostics Market Strategic Insights
Middle East and Africa Point-of-Care Molecular DiagnosticsMarket Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 94.0 Million |
| Market Size by 2028 | US$ 212.9 Million |
| CAGR (2021 - 2028) | 12.4% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product & Services
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
Middle East and Africa Point-of-Care Molecular Diagnostics Market Country and Regional Insights
